Compositions and methods for reducing serum triglycerides

Patent metadata

Field	Value
Publication number	US-11633471-B2
Application number	US-201916977648-A
Country	US
Kind code	B2
Filing date	Mar 6, 2019
Priority date	Mar 6, 2018
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.

First claim

What is claimed is:

1. An immunogen comprising:
a virus-like particle; and
an antigen linked to the virus-like particle, the antigen comprising an antigenic portion of SEQ ID NO:1.

2. The immunogen of claim 1 , wherein the antigen comprises an amino acid sequence having at least 80% sequence similarity to amino acids 32-47 of SEQ ID NO:1.

3. The immunogen of claim 1 , wherein the antigen comprises an amino acid sequence having at least 80% sequence similarity to amino acids 32-57 of SEQ ID NO:1.

4. The immunogen of claim 1 , wherein the virus-like particle comprises one or more Qbeta coat proteins.

5. The immunogen of claim 4 , wherein the antigen is linked to the VLP through a Gly-Gly-Gly-Cys (SEQ ID NO:6) linker at the C-terminal of the antigen.

6. A composition comprising:
the immunogen of claim 1 ; and
a pharmaceutically-acceptable carrier.

7. The composition of claim 6 , further comprising an adjuvant.

8. A method of reducing serum triglycerides in a subject, the method comprising administering a therapeutically effective amount of the immunogen of claim 1 to the subject.

9. The method of claim 8 , wherein the immunogen is administered in combination with an adjuvant.

10. The method of claim 8 , wherein the immunogen is administered in combination with at least one additional therapeutic agent.

11. The method of claim 10 , wherein the additional therapeutic agent comprises a statin or a fibric acid derivative.

12. A nucleic acid encoding the immunogen of claim 1 .

13. An expression vector comprising the nucleic acid of claim 12 .

14. A host cell comprising the expression vector of claim 13 .

Assignees

• Unm Rainforest Innovations
• Us Health
• Chackerian Bryce
• Remaley Alan
• Amar Marcelo
• Fowler Alexandra

Inventors

• Chackerian Bryce
• Remaley Alan
• Amar Marcelo
• Fowler Alexandra

Classifications

• A61K2039/6075

  Viral proteins · CPC title

• C12N2795/18122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• A61K39/385 Primary

  Haptens or antigens, bound to carriers · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K2039/5258

  Virus-like particles · CPC title